Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,770 | 278 | 1,415 |
| Samples | 580 | 160 | 409 |
| Peptides | 354 | 58 | 288 |
Function
KCNN3 · Potassium calcium-activated channel subfamily N member 3
Action potentials in vertebrate neurons are followed by an afterhyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the firing pattern of the neuron. Each component of the AHP is kinetically distinct and is mediated by different calcium-activated potassium channels. This gene belongs to the KCNN family of potassium channels. It encodes an integral membrane protein that forms a voltage-independent calcium-activated channel, which is thought to regulate neuronal excitability by contributing to the slow component of synaptic AHP. This gene contains two CAG repeat regions in the coding sequence. It was thought that expansion of one or both of these repeats could lead to an increased susceptibility to schizophrenia or bipolar disorder, but studies indicate that this is probably not the case. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000271915 | Q9UGI6 | 676 | 331 |
| ENST00000618040 | A0A087WYJ0* | 519 | 312 |
| ENST00000361147 | Q9UGI6-2 | 290 | 203 |
| ENST00000358505 | Q9UGI6-3 | 285 | 199 |
Gene Properties
Recurrent Mutations
All 331 amino-acid changes on canonical ENST00000271915 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KCNN3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KCNN3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Chordoma | 2/7 29% | 0/13 0% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Rhabdomyosarcoma | 0/33 0% | 9/171 5% |
| Melanoma | 13/210 6% | 60/1899 3% |
| Endometrial Carcinoma | 4/42 10% | 17/612 3% |
| Colorectal Carcinoma | 14/143 10% | 80/3239 2% |
| Germ Cell Tumour | 0/25 0% | 5/169 3% |
| Hodgkins Lymphoma | 3/16 19% | 0/122 0% |
| Gastric Carcinoma | 9/74 12% | 28/1809 2% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 16/1390 1% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 7/810 1% |
| Non-Cancerous | 2/104 2% | 13/830 2% |
| Neuroendocrine Tumour | 10/154 6% | 1/577 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 22/1592 1% |
| Mesothelioma | 3/62 5% | 0/165 0% |
| Other Solid Cancers | 1/94 1% | 17/1515 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Hepatocellular Carcinoma | 3/46 7% | 22/2210 1% |
| B-Cell Non-Hodgkins Lymphoma | 8/88 9% | 20/2534 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Ewings Sarcoma | 3/63 5% | 0/262 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Other Sarcomas | 5/69 7% | 1/699 0% |
| Glioma | 3/52 6% | 13/2127 1% |
Mutation Distribution
Where KCNN3 is mutated · all tissues, split by cell line vs tissue
How many mutations in KCNN3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,770 mutations in KCNN3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|